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Normal colonic mucosa in hereditary non-polyposis colorectal cancer
shows no generalised increase in somatic mutation
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S_mmimary Hereditary non-polyposis colorectal cancer (HNPCC) has recently been linked to germline defects
of DNA repair genes. Colorectal tumours in HNPCC frequently show DNA microsatellite instability, but it is
not certain whether this mutator phenotype occurs throughout the morphologically normal colonic mucosa.
We have previously used the mPAS histochemical technique in human colorectal mucosa to identify a
polymorphism for O-acetyltransferase activity that shows monogenic inheritance and to show that crypt-
restricted loss of O-acetyltransferase activity in heterozygotes is due to somatic mutation. We have now used
this histochemical technique to measure the somatic mutation frequency in the uninvolved colon of 12
heterozygous patients with HNPCC, 15 with ileocaecal Crohn's disease and 16 with sporadic colorectal cancer
(CRC). HNPCC patients showed a significant increase in mutation frequency with age (Mann-Whitney U.
P=0.02). In HNPCC patients aged <49 years the mean stem cell mutation frequency was significantly lower
than in the slightly younger group of patients with Crohn's disease (0.8 ± 0.9 x 10-' vs 3.5 ± 3.3 x 10-4,
P<0.01), probably reflecting an increased mutation rate relating to chronic mucosal damage in Crohn's
disease. Although not statistically significant, the stem cell mutation frequency was slightly less in HNPCC
patients >50 years than in sporadic CRC cases (4.9 ± 3.4 x 10-4vs 5.9 ± 3.6 x 10-4, P>0.5). We conclude
that germline defects in HNPCC do not result in a generalised increase in liability to mutation in normal
colonic mucosa but that a second, somatic, event is required. We postulate that this second event occurs in
crypt stem cells at low frequency, giving rise to scattered individual crypts composed of mutation-prone cells.
The cells in these crypts are then at high risk of acquiring the mutations that lead to adenomas, and to rapid
progression to carcinoma.
Keywords: somatic mutation; HNPCC; colorectal cancer; Crohn's disease
Colorectal carcinoma (CRC) is known to occur as a familial
tumour as part of two distinct syndromes, familial
adenomatous polyposis (FAP) and hereditary non-polyposis
colorectal cancer (HNPCC). The gene for FAP (APC) has
been identified on chromosome 5q21 (KinzAer et al., 1991),
and inheritance of a mutated allele is associated with the
development during the second or third decade of life of very
many colorectal adenomas, a small number of which are
highly likely to progress to adenocarcinoma in early to mid
adult life. HNPCC appears to be a more genetically
heterogeneous condition, in that inherited abnormalities of at
least four genes on chromosomes 2p (Peltomaki et al., 1993),
2q (Nicolaides et al., 1994), 3p (Lindblom et al., 1993) and
7p (Nicolaides et al., 1994) appear to be involved in different
kindreds. CRC in HNPCC usually presents later in life than
in FAP, and is more often right-sided, more frequently dip-
loid or near-diploid and possibly more often of mucinous or
signet ring cell type than sporadic CRC (Lynch et al., 1993).
While multiple carcinomas may occur, the background bowel
rarely contains more than a few adenomas, although these
are often larger and are claimed to be more prone to malig-
nant progression than their sporadic counterparts (Jass and
Stewart, 1992). Extracolonic tumours occur in both FAP and
HNPCC patients, notably adenomas and carcinomas of the
more proximal gastrointestinal tract, desmoid tumours,
thyroid, brain and liver tumours in FAP (Phillips et al., 1994)
and endometrial, gastric, ovarian and urinary tract car-
cinomas in HNPCC (Lynch et al., 1993).
The APC gene is thought to act as a tumour-suppressor
gene and, although the function of its product is not estab-
lished, there is evidence to suggest that it is involved in cell
adhesion (Su et al., 1993). The four putative HNPCC genes
so far identified, on the other hand, appear to be involved in
DNA repair. Colorectal adenomas and carcinomas, and ext-
racolonic carcinomas, of HNPCC patients show a high fre-
quency of DNA microsatellite instability (Aaltonen et al.,
1994), and human homologues of the prokaryotic DNA
mismatch repair genes mutS and mutL map to the regions of
chromosomes 2, 3 and 7 that have been shown by linkage
studies to bear the HNPCC loci. Moreover, germline muta-
tions of these repair genes occur in affected patients (Fishel et
al., 1993; Leach et al., 1993; Bronner et al., 1994; Nicolaides
et al., 1994). HNPCC patients might therefore be expected to
show an increased frequency of somatic mutation in a wide
range of other genes. Loss of heterozygosity for
chromosomes 2 or 3 is not common in HNPCC tumours
(Aaltonen et al., 1993; Lindblom et al., 1993) and it is not
certain whether the gene is acting dominantly, conferring
increased mutation in the normal colon as well as in
tumours, or whether its action is confined to tumours.
Evidence suggesting- the latter is derived from the fact that a
lymphoblastoid cell line from an HNPCC-affected individual
was proficient in mismatch repair (Parsons et al., 1993) and
that normal tissue (of unspecified type) from HNPCC
patients was not found to show microsatellite instability
(Aaltonen et al., 1993). However, the possibility that the
inherited DNA defect is confined to tissues with an increased
incidence of cancer, e.g. colonic mucosa, is not excluded. We
have therefore set out to determine whether the somatic
mutation rate is increased in the morphologically normal-
appearing colon of HNPCC patients.
We have shown that a polymorphism exists in human
colon for the O-acetylation of sialic acid in mucus glycop-
roteins which can be demonstrated in tissue sections using
mPAS histochemistry (Fuller et al., 1990; Campbell et al.,
1994a). This technique, which is a modification of the
periodic-acid Schiff procedure, allows non-O-acetylated
sialomucins to be distinguished from O-acetylated
sialomucins (Veh et al., 1992). In the UK approximately 10%
of the adult population show a phenotype resulting from low
or absent mucus glycoprotein O-acetylation, while about
90% show high O-acetylation. Approximately one-half of
adults with the high-activity phenotype show infrequent scat-
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tered discordant low-activity crypts. The hypothesis that
these discordant crypts are the result of somatic mutation in
crypt stem cells in heterozygous individuals has been verified
by showing that they are lacking in children, and that they
increase in frequency after exposure to a mutagen (Fuller et
al., 1990; Campbell et al., 1994b). Although the gene
involved has not been identified, a monogenic basis for the
polymorphism has been confirmed by showing that the
phenotype frequency varies between Sino-Japanese and other
races, but that in all populations the phenotype frequency is
close to that predicted by the Hardy-Weinberg law (Camp-
bell et al., 1994a). Most discordant crypts in adults are
wholly involved and are considered to represent stem cell
mutations which accumulate with time. A minority show
partial involvement; those from observations in man and
animals have been shown to represent recent mutations
(Campbell et al., 1994b). We have therefore quantified the
frequency of discordant crypts in microscopically normal
colon from patients with HNPCC, and compared this with
their frequency in uninvolved colon from patients with either
Crohn's disease (for younger HNPCC patients) or sporadic
right-sided CRC (for older HNPCC patients). These two
groups were chosen for the comparison because of the
unavailability of an adequate number of right-sided colonic
resection specimens from normal individuals with a wide age
range.
Materials and methods
Twenty six HNPCC patients who had undergone large bowel
resection for CRC were identified from registers maintained
in Cambridge and Cardiff. They were derived from a total of
19 families, and all satisfied the Amsterdam criteria for a
diagnosis of HNPCC (Vasen et al., 1991) with (a) three or
more relatives with histologically verified CRC, one of whom
is a first-degree relative of the other two (b) CRC involving
at least two generations and (c) one or more CRCs diag-
nosed before the age of 50 years. In 19 cases the CRC
occurred proximal to the splenic flexure. None of the patients
had been treated with radiotherapy or chemotherapy.
Paraffin blocks from these HNPCC specimens, from 32 right
hemicolectomy specimens for ileocaecal Crohn's disease and
from 40 consecutive hemicolectomy specimens for sporadic
primary right-sided CRC collected prospectively were ret-
rieved from departmental files. None of these patients had
received radiotherapy or cancer chemotherapy, but two of
the Crohn's disease patients had received the mutagen
azathioprine for immunosuppression.
Blocks of uninvolved microscopically normal colonic resec-
tion margin mucosa were selected and 5 Lm step sections, cut
at 80pm intervals apart, were stained by the mPAS reaction
(Veh et al., 1982). In this technique the oxidation step of a
standard periodic acid-Schiff reaction is modified (using
1 mM sodium periodate at 4"C for 10 min) such that non-O-
acetylated sialomucins are oxidised and subsequently stained
magenta by the Schiff reagent while O-acetylated sialomucins
are not. The total number of crypt profiles in each patient's
sample was determined by counting the number of crypt
profiles in the central step section manually using a hand-
held tally and multiplying this by the number of step sections
studied. At least 10000 crypt profiles were counted in each
case (means 13 898 for HNPCC, 14 215 for Crohn's disease,
20 135 for sporadic right-sided CRC) as samples of this size
are necessary for reliable phenotyping and meaningful interp-
retation of results (Campbell et al., 1994a, b). For each case
the phenotype was determined and in those exhibiting the
heterozygous (high activity with scattered discordant low-
activity crypts) phenotype the frequency of discordant crypts
recorded. Each discordant crypt was categorised as being
wholly involved when all mucin-containing cells in the profile
showed the low-activity phenotype or partially involved when
both phenotypes were present. The distribution of the three
phenotypes in each of the three groups studied was compared
with that predicted by the Hardy-Weinberg law (Vogel and
Motulsky, 1986) using the x2 test as described previously
(Campbell et al., 1994a) and the frequencies of discordant
(mutated) crypts in each group were compared using the
Mann-Whitney U-test.
Results
Table I shows the age, sex and mPAS phenotype distribu-
tions in the three patient groups studied. As would be
expected, patients undergoing right hemicolectomy for Croh-
n's disease were significantly younger than those with
sporadic CRC, while patients with HNPCC had a broad age
range. The frequency distribution of the three mPAS
phenotypes was similar in alt three patient groups, and
showed no significant difference (z, P>0.9) from that
predicted by the Hardy-Weinberg law for a single polymor-
phic gene.
Table II shows the frequencies of discordant (mutated)
crypts in patients with scattered mPAS-positive crypts in a
predominantly mPAS-negative background, i.e. those
patients considered to be heterozygous for O-acetyl-
transferase activity and therefore informative for measuring
the frequency of somatic mutation. Since HNPCC patients
showed a much wider age range than the other two groups,
they have also been divided into those aged <49 years and
those >50 years. This is particularly important for the
comparison of wholly mutated crypt frequencies because they
result from fixed stem cell mutations and reflect the lifetime
accumulated mutational load (Campbell et al., 1994b).
In informative HNPCC patients the total frequency of
mutated crypts ranged from 0.7 x 10-4 to 12.7 x 10-4. The
mean frequency in the five patients aged 28-48 years was
1.5 ± 0.8 x 10-4 (median 1.0 x 10-4), and in the seven
patients aged 51-80 years it was 6.3 4.3 x 10-4 (median
4.3 x 10-4), a significant difference (Mann-Whitney U,
P = 0.02) that was largely accounted for by a difference in
the frequencies of wholly involved crypts (P = 0.01). The
frequency of partially involved crypts was not significantly
different in the two age groups.
Table I mPAS phenotype distributions in the three patient groups studied
mPas Phenotype
Uniform mPAS negative
Nwnber Medin Uniform mPAS with discordant
of M:F age mPAS negative crypts
cases ratio (range) positive observed predicted observed predicteaw
HNPCC 26 1.0:1.0 47 2 12 13 12 11
(28-80)
Crohn's 32 1.0:2.0 30 2 15 18 15 12
disease (19-53)
Right-sided 40 1.0:1.5 72 5 19 17 16 18
CRC (47-94)
aPredictions according to the Hardy-Weinberg law(Vogel andMotulsky, 1986) based onthefrequency of
mPAS-positive phenotypes.
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Table H Frequencies of discordant (mutated) crypts in informative patients (presumed
heterozygous for O-acetyltransferase activity)
Number of Meanfrequency ofmutated crypts x 10'
informative Median age (median)
cases (range) Wholly involved Partiallv involved Total
HNPCC 12 52 3.2 3.4** 1.1 1.3 4.3 ±4.1
(all) (28-80) (1.7) (1.0) (3.0)
HNPCC 5 32 0.8 ± 0.9*+ 0.7 ± 0.7 1.5 ± 0.8t
<49 years (28-48) (0.7) (0.9) (1.0)
HNPCC 7 56 4.9 ± 3.4* 1.4 ± 1.6 6.3 ± 4.3t
>50 years (51-80) (3.6) (1.0) (4.3)
Crohn's 15 27 3.5 ± 3.3+ 0.7 ± 1.4 4.2 ± 4.0
disease (19-46) (2.4) (0) (3.1)
Right-sided 16 75 5.9 ± 3.6** 0.6 ± 0.6 6.6 ± 4.0
CRC (62-94) (5.5) (0.5) (6.1)
Statistically significant differences (Mann-Whitney U) between groups are: * P = 0.01 for
wholly involved crypts, young vsold HNPCCpatients. **P<0.05forwholly involved crypts, all
HNPCC patients vs right-sided CRC. tP = 0.02 for all (wholly + partially) involved crypts.
young vsold HNPCC patients. P<0.01 forwholly involved crypts, young HNPCC vs Crohn's
disease.
Informative patients with Crohn's disease were aged 19-46
years (median 27 years) and had total mutated crypt frequen-
cies ranging from 0.9 x 10-4 to 15.5 x 10-4 with a mean of
4.2 ± 4.0 x 10-4 and a median of 3.1 x 10-4. However the
two highest frequencies (15.5 x 10-4 in a 36-year old and
8.0 x 10-4 in a 26-year old) were found in the two patients
who had received preoperative azathioprine treatment. Com-
parison of the discordant crypt frequencies in all 15 infor-
mative Crohn's disease patients with the similarly aged
younger group of five HNPCC cases shows a significantly
higher frequency of wholly involved crypts in the Crohn's
disease group (P<0.01), but not of partially involved crypts
(P>0.3). Even when the two azathioprine-treated patients
are excluded the difference for wholly involved crypts re-
mains significant (P<0.02).
The 16 informative patients with sporadic right-sided CRC
were aged 62-94 years (median 75 years). Their mean total
mutated crypt frequency was 6.6 ± 4.0 x 10-4 (median
6.1 x 10-4), ranging from 0.5 to 12.0 x 10-4. Comparison of
the discordant crypt frequencies in these cases with all 12
HNPCC cases showed a significantly increased frequency of
wholly mutated crypts in those with sporadic CRC
(P<0.05). However, this difference can be attributed to the
different ages of the patients in the two groups. When the
comparison is confined to the seven HNPCC patients aged
>50 years (median 56 years) the statistical significance of
the difference disappears (P = 0.5). No significant difference
was found in the frequencies of partially involved discordant
crypts between HNPCC and sporadic CRC patients.
The main finding in this study is that the somatic mutation
frequency in the non-tumorous background colonic mucosa
of patients with HNPCC, as assessed by mPAS histochemis-
try, is not significantly raised when compared with age-
matched patients with sporadic right-sided CRC, and is
significantly lower than that found in age-matched patients
with Crohn's disease when assessed by the frequency of
accumulated stem cell mutations (i.e. wholly involved discor-
dant crypts). Our findings therefore support those of
molecular studies in other tissues derived from HNPCC
patients, and suggest that there is no generalised tissue-
specific mutator phenotype in the colonic epithelium, the cell
lineage in which most tumours arise in this inherited cancer
syndrome. However, we cannot exclude the possibility that
the gene responsible for O-acetyltransferase activity is
mutated by a different mechanism from that relevant to
HNPCC. The fact that the colonic mutation frequency in the
young (<49 years) group of HNPCC patients was lower
than in age-matched Crohn's disease patients suggests that it
may represent the 'normal' cumulative mutation frequency at
this age. While it is possible that the sporadic CRC group
contains unrecognised HNPCC cases, we believe that this is
unlikely to have had a major influence on the findings
because the age distribution and frequency of somatic muta-
tion in our patients with right-sided CRC were not
significantly different from a previously reported group of
rectal cancer patients (Campbell et al., 1994b).
Since germline defects of the various genes resulting in
HNPCC syndromes do not by themselves lead to a detectable
generalised increased mutation frequency in the colon, a
second event is needed to trigger the cascade of events
leading to carcinogenesis. This is presumably a mutation in
another gene which, together with the inherited mutation,
allows expression of the increased liability to mutation. The
nature of the second mutation can only be a matter for
speculation at present. The simple explanation, that it is a
somatically acquired defect in the second allele leading to
loss of function of the HNPCC gene, has been questioned
because loss of heterozygosity (LOH) of linked markers for
the relevant chromosome loci is not a frequent finding in
HNPCC tumours (Aaltonen et al., 1993; Lindblom et al.,
1993). However, somatic point mutation of the second (wild-
type) allele has been descnbed in two CRCs in HNPCC
patients with germline mutations of either mutL or mutS
homologues (Leach et al., 1993; Nicolaides et al., 1994),
indicating that this could still be an important route for
acquiring the mutator phenotype. Another possibility is that
liability to increased mutation requires somatic mutation of a
second gene for its expression (Leach et al., 1993). If the
presumptive second mutation were to occur at the same
frequency as the mutation we have observed in this study,
this would imply that by the age of 50 years only some three
or four crypts in every 10000 would have acquired an in-
creased somatic mutation rate. This would not be a
sufficiently common event to be detectable by current
methods of estimating somatic mutation rates in vivo. How-
ever, it could well be sufficient to result in the increased
frequency of CRC in HNPCC patients, particularly when it
is remembered that an accelerated mutation rate is likely to
increase the chance of mutation in other DNA repair genes
with a cascade effect.
The finding of an increased somatic mutation frequency in
the colons of Crohn's disease patients is of interest, and is
probably related to increased regenerative epithelial prolifera-
tion in chronic colitis. It is likely to be related to the known
increased risk of colorectal cancer in chronic inflammatory
bowel disease, both Crohn's colitis and ulcerative colitis
(Gillen et al., 1994). The fact that the highest mutation
frequencies in Crohn's disease patients occurred in the two
who had received azathioprine would be predicted from
treatment with a known mutagen, and raises concerns that
azathioprine therapy may add to the carcinogenic risk in
inflammatory bowel disease. A recent retrospective study ofSomatiicmubtio in HNPC OO- GT Wdhams et a
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long-term neoplasia risk after azathioprine treatment in
patients with Crohn's disease and ulcerative colitis (Connell
et al., 1994) found a significant 2.5 fold increase in all
neoplasms after more than 5 years of azathioprine, and a
17-fold increase in CRC, although this did not reach statis-
tical significance (the absolute number of tumours was
small). The same study compared the frequency of CRC in
azathioprine-treated ulcerative colitis patients with matched
patients who had not received the drug. Only a small non-
significant increase was observed in the treated group, but
this included an unspecified proportion of patients with short
treatment times. Further studies of the risks of long-term
azathioprine therapy are needed.
Our observations can be correlated with the clinical
findings in FAP and HNPCC. The high frequency of colonic
adenomas in FAP is consistent with a single somatic muta-
tion of the normal allele of the APC gene leading to
adenoma formation in these patients. These adenomas indi-
vidually have a relatively low risk of progression to malig-
nancy but they are so numerous that malignancy is virtually
certain to occur in one or more polyps during the lifetime of
an FAP patient. The infrequency of adenomas in HNPCC
patients suggests that a single somatic mutation is not
sufficient, but that at least two events are needed for
adenoma formation. Our findings show that there is no
general increase in somatic mutation, and are compatible
with a sequence of events in which a single somatic mutation
leads to an increased propensity to somatic mutation in the
involved crypt only. A significant proportion of these
'mutation-prone' crypts then acquire the further events
needed to give rise to an adenoma, also mutation prone, and
with a high chance of progression to malignancy. This
hypothesis is supported by the high frequency of microsatel-
lite instability in both adenomas and carcinomas in HNPCC
(Aaltonen et al., 1994), and by the suggestion that adenomas
in these patients are more prone to malignant progression
than sporadic adenomas or those of FAP (Jass and Stewart,
1992).
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